Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination

Based on its clinical benefits, Trikafta — the combination of folding correctors VX-661 (tezacaftor), VX-445 (elexacaftor), and the gating potentiator VX-770 (ivacaftor) — was FDA approved for treatment of patients with cystic fibrosis (CF) carrying deletion of phenylalanine at position 508 (F508del...

Descripción completa

Detalles Bibliográficos
Autores principales: Veit, Guido, Roldan, Ariel, Hancock, Mark A., Da Fonte, Dillon F., Xu, Haijin, Hussein, Maytham, Frenkiel, Saul, Matouk, Elias, Velkov, Tony, Lukacs, Gergely L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526550/
https://www.ncbi.nlm.nih.gov/pubmed/32853178
http://dx.doi.org/10.1172/jci.insight.139983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526550/
https://www.ncbi.nlm.nih.gov/pubmed/32853178
http://dx.doi.org/10.1172/jci.insight.139983

Ejemplares similares